Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...

Freenome is conducting the PREEMPT CRC study, a >35,000-person prospective study for colorectal cancer (CRC) evaluating Freenome's blood-based screening test for CRC in the average-risk population.

The results of South San Francisco-based Freenome Holdings Inc.’s 42,000-person study won’t be released until the second half of this year. But leaders of the privately held company and its ...

Freenome said the money would be used for a validation study and would then submit an application for its colorectal cancer screening test to both the U.S. Food and Drug Administration (FDA) and ...

If Freenome’s multiomics approach can help us achieve that goal, it would be wonderful. This is why our BrightEdge impact fund has chosen to invest in Freenome’s work.” ...

Freenome Holdings Inc. has raised $270 million to pursue U.S. regulatory approval of a blood test to detect colorectal cancer, part of a push by molecular-testing companies to enable earlier ...